284492-02-0 Usage
Uses
Used in Pharmaceutical Research and Development:
3-N-FMOC-3-(4-METHOXYPHENYL)PROPIONIC ACID is used as a building block for the synthesis of various peptides and pharmaceutical compounds, leveraging its chemical structure and reactivity to contribute to the creation of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-N-FMOC-3-(4-METHOXYPHENYL)PROPIONIC ACID is used as a key intermediate, facilitating the construction of complex organic molecules and aiding in the advancement of chemical methodologies.
Used in Drug Delivery Systems Development:
3-N-FMOC-3-(4-METHOXYPHENYL)PROPIONIC ACID is utilized in the study and development of drug delivery systems, where its protective group can be strategically removed to release the active pharmaceutical ingredient at the desired site of action, thereby enhancing the efficacy and targeting of therapeutic interventions.
Used in Targeted Therapies:
In targeted therapy research, 3-N-FMOC-3-(4-METHOXYPHENYL)PROPIONIC ACID is employed to develop compounds that can specifically interact with molecular targets, such as receptors or enzymes, to treat diseases with high precision and minimal side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 284492-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,4,4,9 and 2 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 284492-02:
(8*2)+(7*8)+(6*4)+(5*4)+(4*9)+(3*2)+(2*0)+(1*2)=160
160 % 10 = 0
So 284492-02-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H23NO5/c1-30-17-12-10-16(11-13-17)23(14-24(27)28)26-25(29)31-15-22-20-8-4-2-6-18(20)19-7-3-5-9-21(19)22/h2-13,22-23H,14-15H2,1H3,(H,26,29)(H,27,28)
284492-02-0Relevant articles and documents
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
